Elsevier,

Experimental Eye Research, Volume 221, August 2022

This research provides the first evidence of AD-related Aβ pathology outside the brain. Lens Aβ can be noninvasively measured in vivo for early AD detection and monitoring.
An Article on depression among middle-aged and older people, in the context of SDG 3, focusing specifically on a machine learning approach to predictors of depression.
An Article on stress-related disorders, in the context of SDG 3, focusing specifically on the association betweent these disorders and mortality.
This Article supports SDGs 3 and 5, investigating the links between intimate partner violence and suicidal thoughts, suicide attempts, and self-harm.
A Viewpoint, in the context of SDG 3 and 9, exploring the impact and potential of China's Smart Eldercare model, which harnesses digital technologies to improve the quality of life of China's fast-expanding ageing population, including nearly 10 million people with Alzheimer's disease.
A Personal View in support of SDGs 3 and 13, summarising the current evidence on climate change and mental health, and outlining opportunities for methodological improvement and innovation in this research field.
A Viewpoint on the interplay between social, climate, and health challenges in Latin America and the Caribbean, in the context of SDGs 3, 10, and 13, highlighting the need to address these challenges with adaption and mitigation policies that prioritise people's health and wellbeing.
A Viewpoint in support of SDGs 3, 13, and 17, proposing a range of strategies for developing a 'public health playbook', to counter the 'corporate playbook' used by powerful commercial actors to protect their business interests at the expense of population health and wellbeing, including numerous health-harming and planet-harming industries, such as tobacco, alcohol, gambling, pharmaceuticals, ultraprocessed foods and beverages, firearms and weapons, automobiles, social media and technology, oil and gas, and chemicals.
A Comment on dementia and Alzheimer's disease costs, in the context of SDG 3, focusing specifically on the costs of care in Europe. Dementia is a syndrome characterized by progressive cognitive and functional impairment, most commonly caused by Alzheimer's disease and other neurodegenerative and cerebrovascular disorders. Costs of care increase dramatically with progressing disease severity, and increasing dementia prevalence due to ageing populations is raising concerns about the sustainability of future costs of dementia care. A new study shows that social welfare systems in Europe cover most of the direct costs of dementia, however they do not protect families and households against the burden of informal care. Meier and colleagues1 set out to calculate the economic costs of dementia in 11 European countries, by combining microdata from a population-based survey with estimates of dementia prevalence. Data for Austria, Belgium, Czechia, Denmark, Estonia, France, Germany, Italy, Slovenia, Spain, and Sweden was obtained from six waves of the Survey of Health, Ageing, and Retirement in Europe (SHARE). The survey captured out-of-pocket expenditures for health and social care as well as unpaid informal care. Costs attributable to dementia were estimated using linear regression, controlling for comorbidities and demographic factors. Finally, costs were combined with prevalence estimates to calculate the annual cost of dementia by country.

Pages